KR102752620B1 - 이중 모드 방사성 트레이서 및 치료법 - Google Patents

이중 모드 방사성 트레이서 및 치료법 Download PDF

Info

Publication number
KR102752620B1
KR102752620B1 KR1020207005589A KR20207005589A KR102752620B1 KR 102752620 B1 KR102752620 B1 KR 102752620B1 KR 1020207005589 A KR1020207005589 A KR 1020207005589A KR 20207005589 A KR20207005589 A KR 20207005589A KR 102752620 B1 KR102752620 B1 KR 102752620B1
Authority
KR
South Korea
Prior art keywords
psma
sifa
nat
bond
dmf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005589A
Other languages
English (en)
Korean (ko)
Other versions
KR20200064057A (ko
Inventor
알렉산더 요세프 우르제르
한스-위르겐 웨스테르
마티아스 요하네스 에이베르
Original Assignee
테크니쉐 우니베르지테트 뮌헨
테크니쉐 우니베르지테트 뮌헨 - 클리니쿰 레흐츠 데르 이사르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테크니쉐 우니베르지테트 뮌헨, 테크니쉐 우니베르지테트 뮌헨 - 클리니쿰 레흐츠 데르 이사르 filed Critical 테크니쉐 우니베르지테트 뮌헨
Priority to KR1020247006169A priority Critical patent/KR20240027896A/ko
Publication of KR20200064057A publication Critical patent/KR20200064057A/ko
Application granted granted Critical
Publication of KR102752620B1 publication Critical patent/KR102752620B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
KR1020207005589A 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법 Active KR102752620B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247006169A KR20240027896A (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
EP17183795.8 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247006169A Division KR20240027896A (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Publications (2)

Publication Number Publication Date
KR20200064057A KR20200064057A (ko) 2020-06-05
KR102752620B1 true KR102752620B1 (ko) 2025-01-10

Family

ID=59501286

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207005589A Active KR102752620B1 (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법
KR1020247006169A Ceased KR20240027896A (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247006169A Ceased KR20240027896A (ko) 2017-07-28 2018-07-30 이중 모드 방사성 트레이서 및 치료법

Country Status (21)

Country Link
US (4) US11413360B2 (https=)
EP (3) EP4424378A3 (https=)
JP (2) JP7059372B2 (https=)
KR (2) KR102752620B1 (https=)
CN (1) CN111132700B (https=)
AU (2) AU2018308699B2 (https=)
BR (1) BR112020001785A2 (https=)
CA (1) CA3071315A1 (https=)
DK (1) DK3658194T3 (https=)
EA (1) EA202090370A1 (https=)
ES (1) ES3011272T3 (https=)
FI (1) FI3658194T3 (https=)
HU (1) HUE070098T2 (https=)
IL (2) IL318092A (https=)
MX (2) MX2020000352A (https=)
NZ (1) NZ760537A (https=)
PL (1) PL3658194T3 (https=)
PT (1) PT3658194T (https=)
SG (1) SG11202000725WA (https=)
WO (1) WO2019020831A1 (https=)
ZA (1) ZA202000467B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE070098T2 (hu) * 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
BR112021012110A2 (pt) 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
AU2021336987A1 (en) 2020-09-03 2023-04-06 Curium Us Llc Radiolabeling and formulation for scale up of 64Cu-dotatate
EP4023250A1 (en) 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
AU2022219543A1 (en) * 2021-02-15 2023-08-17 Technische Universität München Dual mode radiotracer and therapeutics
IL307381A (en) * 2021-04-02 2023-11-01 Advanced Accelerator Applications Diagnostic methods of prostate cancer
MX2023013485A (es) * 2021-05-14 2023-12-07 Univ Muenchen Tech Radiofarmacos ligandos del receptor de la somatostatina y precursores de los mismos.
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4380629A1 (en) * 2021-08-05 2024-06-12 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
JP2025525111A (ja) 2022-07-29 2025-08-01 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
AU2023345654A1 (en) * 2022-09-20 2025-02-27 Technische Universität München Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
KR20250073273A (ko) 2022-09-23 2025-05-27 누클리디움 아게 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
AU2023379454A1 (en) * 2022-11-14 2025-05-29 Aktis Oncology, Inc. Decreased retention of miniproteins in kidney
TW202530249A (zh) 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
WO2025250644A1 (en) * 2024-05-28 2025-12-04 Case Western Reserve University Fluorescent nuclide-containing agents for detecting and treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
JP2005519861A (ja) * 2001-07-27 2005-07-07 ターゲサム・インコーポレーテッド 治療剤及び撮像剤としての脂質構築物
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
RU2743781C2 (ru) * 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
US10800797B2 (en) * 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
HUE070098T2 (hu) 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
BR112020011727A2 (pt) * 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry, 26(12), 2015.12., pp.2350-2359
Bioconjugate Chemistry, 27(2), 2016.02., pp.267-279

Also Published As

Publication number Publication date
US11413360B2 (en) 2022-08-16
US20260021211A1 (en) 2026-01-22
EP3658194A1 (en) 2020-06-03
MX2023007914A (es) 2023-07-13
CN111132700A (zh) 2020-05-08
IL272291B2 (en) 2025-06-01
BR112020001785A2 (pt) 2020-09-29
IL272291A (en) 2020-03-31
US20200197545A1 (en) 2020-06-25
IL272291B1 (en) 2025-02-01
EP4424378A2 (en) 2024-09-04
ES3011272T3 (en) 2025-04-07
KR20200064057A (ko) 2020-06-05
EP4424378A3 (en) 2024-12-11
US12453787B2 (en) 2025-10-28
KR20240027896A (ko) 2024-03-04
EP4000640A1 (en) 2022-05-25
FI3658194T3 (fi) 2025-02-28
HUE070098T2 (hu) 2025-05-28
WO2019020831A1 (en) 2019-01-31
US12390540B2 (en) 2025-08-19
MX2020000352A (es) 2020-08-17
IL318092A (en) 2025-02-01
EA202090370A1 (ru) 2020-05-25
AU2024200440B2 (en) 2025-04-24
JP2020528461A (ja) 2020-09-24
PT3658194T (pt) 2025-02-13
PL3658194T3 (pl) 2025-09-15
EP3658194B1 (en) 2024-11-27
US20250121102A1 (en) 2025-04-17
CN111132700B (zh) 2022-12-13
JP2022101601A (ja) 2022-07-06
NZ760537A (en) 2026-01-30
AU2024200440A1 (en) 2024-02-08
JP7059372B2 (ja) 2022-04-25
DK3658194T3 (da) 2025-02-17
AU2018308699B2 (en) 2023-11-30
ZA202000467B (en) 2022-06-29
US20220370649A1 (en) 2022-11-24
AU2018308699A1 (en) 2020-01-23
SG11202000725WA (en) 2020-02-27
CA3071315A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
KR102752620B1 (ko) 이중 모드 방사성 트레이서 및 치료법
KR102951950B1 (ko) 암 진단 영상화제들
CN113677400B (zh) 结合psma的双模式放射性示踪剂及治疗剂
EP4291250B1 (en) Dual mode radiotracer and therapeutics
US20230277698A1 (en) Silicon-containing ligand compounds
HK40022705A (en) Dual mode radiotracer and -therapeutics
HK40022705B (en) Dual mode radiotracer and -therapeutics
EA052134B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство
HK40055543A (en) Cancer diagnostic imaging agents
HK40055543B (en) Cancer diagnostic imaging agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G18 Pte requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G18-TEX-PA0101 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 16, Claim Number : 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, Period Limitation Text : 359, Comment Text : 261